Benjamin L. Palleiko Sells 5,104 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 5,104 shares of KalVista Pharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total value of $50,121.28. Following the sale, the chief executive officer now owns 278,855 shares in the company, valued at $2,738,356.10. This trade represents a 1.80 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $10.64 on Friday. The company’s 50 day simple moving average is $8.84 and its 200-day simple moving average is $10.43. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $15.50. The firm has a market capitalization of $525.83 million, a PE ratio of -2.92 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.01. As a group, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. SG Americas Securities LLC grew its stake in KalVista Pharmaceuticals by 10.0% in the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 1,319 shares during the period. HighVista Strategies LLC grew its position in shares of KalVista Pharmaceuticals by 4.5% in the third quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock valued at $386,000 after purchasing an additional 1,432 shares during the period. Legal & General Group Plc grew its position in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 1,494 shares during the period. JPMorgan Chase & Co. increased its stake in KalVista Pharmaceuticals by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after purchasing an additional 1,670 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 2,043 shares during the period.

Analysts Set New Price Targets

KALV has been the topic of several research analyst reports. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. Finally, Bank of America started coverage on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).